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Background: As the management of patients treated with anticoagulants and antiplatelet drugs entails balancing
coagulation levels, we evaluated the net clinical benefit of warfarin and aspirin on stroke in a large cohort of
patients with atrial fibrillation (AF).
Methods: A population-based cohort study of all patients at least 18 years of age with a first-ever diagnosis of
chronic AF during the period 1993–2008 was conducted within the United Kingdom General Practice Research
Database. A nested case–control analysis was conducted to estimate the risk of ischemic stroke and intracranial
hemorrhage associated with the use of warfarin and aspirin. Cases were matched up to 10 controls on age, sex,
and date of cohort entry. The adjusted net clinical benefit of warfarin and aspirin (expressed as the number of
strokes prevented per 100 persons per year) was calculated by subtracting the ischemic stroke rate (prevented by
therapy) from the intracranial hemorrhage (ICH) rate (increased by therapy).
Results: The cohort included 70,766 patients newly-diagnosed with chronic AF, of whom 5519 experienced an ischemic
stroke and 689 an ICH during follow-up. The adjusted net clinical benefit of warfarin was 0.59 (95% CI: 0.45, 0.73).
However, the benefit was not seen for patients below (0.08, 95%: -0.38, 0.54) and above (−0.49, 95% CI: -1.13, 0.15)
therapeutic range. The net clinical benefit of warfarin, apparent after 3 months of continuous use, increased as a function
of CHADS2 score. The net clinical benefit was not significant with aspirin (−0.07, 95% CI: -0.22, 0.08), though it was seen
in certain subgroups.
Conclusions: Warfarin provides a net clinical benefit in patients with atrial fibrillation, which is maintained with longer
duration of use, particularly when used within therapeutic range. A similar net effect is not as clear with aspirin.
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For the past 50 years, warfarin has been the mainstay treat-
ment for patients with atrial fibrillation (AF), a population
at an increased risk of thromboembolic events [1]. Its effi-
cacy has been well established in randomized controlled
trials (RCTs), decreasing the risk of ischemic stroke by over
60% [2,3]. However, this therapy remains largely underused
in clinical practice [4–6], in part because of its narrow* Correspondence: samy.suissa@mcgill.ca
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reproduction in any medium, provided the ortherapeutic range, and its association with a number of
important complications.
The use of this therapy must be balanced between its
benefits and risks, with intracranial hemorrhage (ICH)
representing the most feared complication of this therapy,
an event associated with a high mortality rate [7]. Recently,
two studies quantified the net clinical benefit of warfarin
using ‘real world’ cohorts of patients with AF [8,9]. In the
first study, Singer et al. [8] showed the net clinical benefit
of warfarin was greatest among high risk patients. Their
analyses included time spent outside therapeutic range
(35% of warfarin exposed time), therefore questions remain
as to the actual net clinical benefit for patients below,
within, and above therapeutic range. Furthermore, the netl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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therapy often used in this population. The second study by
Olesen et al. [9] found a positive net clinical benefit with
warfarin among patients at high risk of stroke and bleed-
ing, and no net clinical benefit with aspirin. The authors
did not have access to INR information, and thus it was
not possible to assess the net clinical benefit of warfarin
according to different levels of anticoagulation.
As novel oral anticoagulants are entering the market,
it is imperative to identify patients most likely to benefit
from warfarin and aspirin therapy. Thus, the objective of
this study was to evaluate the net clinical benefit of war-
farin, overall and stratified according to different levels
of anticoagulation, as well as that of aspirin in a large
population-based cohort of patients with chronic AF.
Methods
Data source
This study was conducted using the General Practice
Research Database (GPRD), a primary care database from
the United Kingdom (UK) [10]. It contains the complete
primary care medical record for more than 10 million
people enrolled in more than 600 general practices. The
geographic distribution of the practices participating in
the GPRD has been shown to be representative of the UK
population, and age and sex distributions of patients in
the GPRD are similar to those reported by the National
Population Census [11]. The recorded information on
diagnoses and drug exposures has been validated and
proven to be of high quality [12–15]. The study protocol
was approved by the Independent Scientific Advisory
Committee of the GPRD and the Research Ethics Com-
mittee of the Jewish General Hospital, Montreal, Canada.
Study population
We identified all patients, at least 18 years of age, diag-
nosed for the first time with chronic AF or atrial flutter
between January 1, 1993 and December 31, 2008 within
the GPRD population. Cohort entry corresponded to the
day of the first diagnosis of chronic AF or atrial flutter.
Patients were required to have at least one year of medical
history in the GPRD prior to cohort entry. We excluded
patients with a history of mitral/aortic valve repair/re-
placement, or hyperthyroidism (either a diagnosis or treat-
ment) at any time prior to cohort entry. All patients were
followed until the first of the following events: ischemic
stroke or ICH (depending on the outcome being studied),
death, end of registration with the general practice, or end
of the study period (December 31, 2008).
Analytic approach
Two nested case–control analyses were performed
within the cohort defined above, each corresponding to
one of the study outcomes (ischemic stroke and ICH),which were identified on the basis of Read codes. This
approach was used because of the time-varying nature of
the exposures, the size of the cohort, and the long dur-
ation of follow-up [16]. In comparison to a full cohort
approach using a survival analysis with time-dependent
variables, a nested case–control analysis is computation-
ally more efficient [17], while producing odds ratios
(ORs) that are unbiased estimators of incidence rate
ratios (RRs) with little or no loss in precision [16–18].
We identified all cases occurring during follow-up, and
the calendar date of each case’s event was defined as the
index date. Up to 10 controls were randomly selected
from the case's risk set, after matching on year of birth,
sex, and date of cohort entry. The date of the risk set was
the index date for the controls.
Exposure assessment
For the purposes of this study, we created an algorithm
that simultaneously estimates warfarin exposure and
therapeutic range at any point in time during follow-up.
This algorithm is an adaptation of two algorithms com-
monly used in AF studies, one devised by Go et al. [19]
(warfarin exposure) and Rosendaal et al. [20] (time in
therapeutic range). Briefly, patients were considered
exposed to warfarin in the presence of a prescription and/
or with an international normalized ratio (INR) measure-
ment performed in the outpatient setting. The latter was
also used to bridge gaps between any two periods of war-
farin prescription coverage. Simple linear interpolation to
classify each day of follow-up in predefined categories of
therapeutic range (INR: <2, INR: 2 – 3, INR: >3, and INR
unknown). A detailed description of this algorithm can be
found in the Additional file 1.
Using the algorithm above, cases and controls were clas-
sified as to whether they were current users of warfarin at
index date, while current use of other antithrombotic ther-
apies (such as aspirin and other antiplatelets) was defined
by the presence of prescriptions in the 90 days prior to
index date. Thus, cases and controls were classified into
one of five mutually exclusive exposure groups: 1) war-
farin monotherapy, 2) aspirin monotherapy, 3) other
antithrombotic therapies (such as clopidogrel) or combi-
nations, 4) past use of any antithrombotic therapy (not
current, but evidence of use in the year prior to index
date), and 5) no use of any antithrombotic therapy in the
year prior to index date. Current warfarin monotherapy
users were further classified according to their anticoagu-
lation level at index date.
Net clinical benefit
Warfarin and aspirin have been shown to decrease the
risk of ischemic strokes (benefits), while increasing the
risk of hemorrhage (risks), with ICH being one of the
most fatal events, in patients with AF. The relationship














79.5 (9.2) 79.5 (9.1) 78.2 (9.6) 78.2 (9.4)
Males, n (%)* 2503 (45.4) 24,979 (45.4) 366 (53.1) 3649 (53.2)
Excessive
alcohol use, n (%)
76 (1.4) 643 (1.2) 14 (2.0) 106 (1.5)
Smoking status,
n (%)
Ever 2253 (40.8) 22,044 (40.1) 357 (51.8) 3240 (47.2)
Never 2709 (49.1) 28,181 (51.2) 291 (42.2) 3237 (47.2)
Unknown 557 (10.1) 4797 (8.7) 41 (6.0) 381 (5.6)
Obesity, n (%)
BMI< 30 3407 (61.7) 34,630 (62.9) 445 (64.6) 4575 (66.7)
BMI≥ 30 810 (14.7) 8716 (15.8) 116 (16.8) 1225 (17.9)
Unknown 1302 (23.6) 11,676 (21.2) 128 (18.6) 1058 (15.4)
Congestive
heart failure, n (%)
1432 (25.9) 13,976 (25.4) 163 (23.7) 1625 (23.7)
Hypertension, n (%) 2992 (54.2) 28,238 (51.3) 414 (60.1) 3676 (53.6)
Diabetes, (%) 528 (9.6) 4458 (8.1) 77 (11.2) 640 (9.3)




297 (5.4) 2275 (4.1) 33 (4.8) 293 (4.3)
Myocardial infarction,
n (%)
696 (12.6) 6554 (11.9) 83 (12.0) 845 (12.3)
Previous cancer, n (%) 1003 (18.2) 10,605 (19.3) 155 (22.5) 1351 (19.7)




421 (7.6) 4094 (7.4) 60 (8.7) 525 (7.7)
ACE inhibitors, n (%) 1738 (31.5) 18,237 (33.1) 259 (37.6) 2565 (37.4)
Angiotensin receptor
blockers, n (%)
397 (7.2) 4572 (8.3) 63 (9.1) 756 (11.0)
Antidepressants, n (%) 706 (12.8) 5404 (9.8) 100 (14.5) 725 (10.6)
Antipsychotics, n (%) 555 (10.1) 3858 (7.0) 52 (7.5) 429 (6.3)
NSAIDs, n (%) 981 (17.8) 9102 (16.5) 88 (12.8) 1001 (14.6)
Statins, n (%) 1294 (23.4) 12,503 (22.7) 211 (30.6) 2032 (29.6)
Azoulay et al. BMC Cardiovascular Disorders 2012, 12:49 Page 3 of 9
http://www.biomedcentral.com/1471-2261/12/49between the benefits and risks of these therapies can be
expressed according to the following mathematical
formula:
Net Clinical Benefit =Adjusted rate difference for
stroke off therapy-on therapy – Weight x Adjusted rate differ-
ence for ICH on therapy-off therapy
For both types of outcomes, we calculated adjusted
rate differences (RD) and corresponding 95% confidence
intervals using the following formula: R0*(1 - RR) for is-
chemic stroke, and R0*(RR - 1) for ICH, where R0 was
the overall rate of each outcome in the cohort, and RR
was the adjusted rate ratio for the relevant outcome in
relation to exposure. As with the study by Singer et al
[8], the adjusted RDs for ICH were multiplied by a
weighting factor, reflecting its relative impact on mor-
bidity and mortality. For comparability with the previous
study [8], we used a factor of 1.5 for ICH, and performed
sensitivity analyses with weights of 1.0 and 2.0.
Statistical analysis
Conditional logistic regression was used to estimate RRs
along with 95% confidence intervals for ischemic stroke
and ICH associated with current use of warfarin mono-
therapy, overall and according to therapeutic range, and
aspirin monotherapy. The reference category for all ana-
lyses consisted of no exposure to any antithrombotic
therapy in the year prior to index date. In addition to
age, sex, year of cohort entry, on which the logistic re-
gression was conditioned, all models were adjusted for
the potential confounders listed in Table 1. The stroke
model was additionally adjusted for CHADS2 score [21],
while the ICH model was additionally adjusted for the
components of that score at index date.
To assess the net clinical benefit of warfarin and aspirin
monotherapy, we calculated adjusted RDs which were then
used to compute the annualized net clinical benefit of war-
farin and aspirin, along with 95% confidence intervals. We
also conducted three subgroup analyses to determine
whether the net clinical benefit of warfarin and aspirin
varied across different groups of patients. For these
analyses, cases and matched controls were stratified
according to whether they had a history of ischemic stroke,
history of any bleed, and CHADS2 score at baseline.
Finally, in a fourth analysis, we assessed whether the net
clinical benefit of warfarin varied as a function of its
duration of use. For this analysis, current warfarin mono-
therapy users were categorized into five groups of continu-
ous use (<3 months, 3–6 months, 6–9 months, 9–
12 months, ≥12 months). All analyses were conducted
using SAS version 9.2 (SAS Institute Inc., Cary, NC).
Results
A total of 70,766 patients met the inclusion criteria
(Figure 1). The mean age at cohort entry was 74.1 (SD:11.8) years, 51.8% were males, and the mean duration
of follow-up was 3.9 (SD: 3.3) years. There were a total
of 275,987 person-years of follow-up, during which
time 5519 patients experienced an ischemic stroke
(overall rate: 2.00% (95% CI: 1.95%, 2.05%) per year),
and 689 patients experienced an ICH (overall rate:
0.25% (95% CI: 0.23%, 0.27%) per year). A total of
35,216 (49.8%) patients were prescribed warfarin at
Figure 1 Study flow chart.
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at baseline, 21.6% had a score of 0, 33.9% had a score of
1, 26.0% had a score of 2, 10.5% had a score of 3, and
7.9% had a score of ≥ 4. Table 1 presents the character-
istics of the cases and matched controls.
As shown in Table 2, current warfarin use was asso-
ciated with a 35% decreased risk of ischemic stroke com-
pared to no use of any antithrombotic therapy. This
effect was driven by being within therapeutic range
(adjusted RR: 0.69, 95% CI: 0.57, 0.83), and having an
unknown therapeutic range (adjusted RR: 0.62, 95% CI:
0.56, 0.69). Current use of aspirin was not associated
with a decreased risk of ischemic stroke. With respect to
ICH, an increased risk was only observed in warfarin
users above therapeutic range (adjusted RR: 3.26, 95%
CI: 1.67, 6.38).
Net clinical benefit of warfarin and aspirin
Table 3 presents the net clinical benefit of warfarin and
aspirin, expressed in number of ischemic strokes pre-
vented per 100 persons per year. Based on a weight of 1.5,
warfarin monotherapy was associated with a net clinical
benefit of 0.59 (95% CI: 0.45, 0.73). This net clinical bene-
fit was mainly driven by patients within range, and those
with an unknown therapeutic range (Table 3). Overall,
aspirin was not associated with a statistically significant
net clinical benefit. Sensitivity analyses using ICH weights
of 1.0 and 2.0 produced similar results.
In subgroup analyses, a high net clinical benefit of war-
farin was observed in patients with a history of ischemic
stroke (3.34, 95% CI: 2.01, 4.67), although a more modest
benefit was also observed in patients with no such history(0.52, 95% CI: 0.38, 0.66). A similar pattern was observed
for aspirin, where a net clinical benefit was observed in
patients with a history of ischemic stroke (1.69, 95% CI:
0.04, 3.33), while no benefit was observed in those with no
such history (−0.07, 95% CI: -0.22, 0.08). In contrast,
patients with no history of bleeds were the ones most
likely to benefit from warfarin therapy (0.65, 95% CI: 0.50,
0.80), while patients with a history of bleeds had no bene-
fit (0.40, 95% CI: -0.11, 0.91). With respect to aspirin, no
net clinical benefit was observed in either those without
and with a history of bleeds (−0.05, 95% CI: -0.21, 0.11
and −0.08, 95% CI: -0.61, 0.46, respectively).
As shown in Figure 2, the net clinical benefit of warfarin
increased as the CHADS2 score increased. With respect
to aspirin, a modest net clinical benefit was observed in
patients with CHADS2 scores of 0 and 1 at baseline, while
no statistically significant net clinical benefit was observed
with other CHADS2 scores (Figure 3). Finally, the net clin-
ical benefit of warfarin became apparent after 3 months of
continuous use and was maintained with longer duration
of use (Figure 4).
Discussion
The results of this large population-based study indicate
that warfarin is associated with a net clinical benefit in
preventing ischemic strokes in patients with AF, while
overall, no net clinical benefit is observed with aspirin.
Furthermore, this study presents for the first time, the
net clinical benefit of warfarin classified according to dif-
ferent levels of anticoagulation. Our results confirm that
the net clinical benefit of warfarin is limited to patients
within therapeutic range, and thus emphasize the need
Table 2 Adjusted rate ratios of cerebrovascular outcomes associated with the use of warfarin and aspirin
Cases/Controls Crude RR Adjusted RR (95 % CI)*
Ischemic stroke 5519/55,022
No use of any therapy 1513/15,499 1.00 1.00 (reference)
Current use of warfarin monotherapy 896/13,238 0.67 0.65 (0.59, 0.71)
Below therapeutic range (INR: <2)† 63/667 0.95 0.93 (0.71, 1.22)
Within therapeutic range (INR: 2–3)† 132/1838 0.71 0.69 (0.57, 0.83)
Above therapeutic range (INR: >3)† 31/361 0.86 0.82 (0.57, 1.20)
Unknown therapeutic range† 670/10,372 0.64 0.62 (0.56, 0.69)
Current use of aspirin monotherapy 2002/18,399 1.11 1.05 (0.98, 1.13)
Intracranial hemorrhage 689/6858
No use of any therapy 114/1365 1.00 1.00 (reference)
Current use of warfarin monotherapy 242/2214 1.41 1.29 (1.00, 1.68)
Below therapeutic range (INR: <2)† 13/126 1.32 1.16 (0.62, 2.16)
Within therapeutic range (INR: 2–3)† 34/356 1.25 1.13 (0.74, 1.72)
Above therapeutic range (INR: >3)† 13/47 3.63 3.26 (1.67, 6.38)
Unknown therapeutic range† 182/1685 1.39 1.29 (0.98, 1.69)
Current use of aspirin monotherapy 172/2210 0.97 0.92 (0.70, 1.19)
Abbreviations: RR: Rate ratio; CI: Confidence interval; INR: International normalized ratio.
*Adjusted for excessive alcohol use, smoking status, obesity, peripheral artery disease, myocardial infarction, previous cancer, prior bleeds, thromboembolic
disorders, ACE inhibitor use, angiotensin receptor blocker use, antidepressant use, antipsychotic use, NSAID use, and statin use. The stroke model was additionally
adjusted for CHADS2 score, while the intracranial hemorrhage model was additionally adjusted for the components of that score.
†Mutually exclusive categories among current users of warfarin monotherapy.
Note: Current users of other antithrombotic therapies or combinations, as well as past users are not displayed in the Table, but were included in the regression
model to allow the proper estimation of treatment effects. These represent 1108 cases and 7886 controls for the ischemic stroke model, and 161 cases and 1069
controls for the intracranial hemorrhage model.
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our results confirm previous findings [8,9] that high risk
patients, such as those with a history of ischemic stroke
and high CHADS2 scores are those most likely to benefit
from this therapy, they also justify physician concerns
that warfarin may not be indicated for patients with a
history of bleeds. Similar patterns were observed with
aspirin in subgroup analyses, although the net clinicalTable 3 Net clinical benefit of warfarin, stratified according to
Adjusted RD*†
Ischemic stroke ǂ Intracranial hem
Current use of warfarin monotherapy 0.70 (0.58, 0.82) 0.07 (0.00, 0.15)
Below therapeutic range (INR: <2) 0.14 (−0.30, 0.58) 0.04 (−0.09, 0.17)
Within therapeutic range (INR: 2–3) 0.62 (0.38, 0.86) 0.03 (−0.06, 0.13)
Above therapeutic range (INR: >3) 0.36 (−0.14, 0.86) 0.56 (0.16, 0.96)
Unknown therapeutic range 0.76 (0.64, 0.88) 0.07 (−0.01, 0.15)
Current use of aspirin monotherapy −0.10 (−0.24, 0.04) −0.02 (−0.07, 0.0
Abbreviations: RD: Rate difference; CI: Confidence interval; INR: International norma
* Per 100 persons per year.
† Adjusted for excessive alcohol use, smoking status, obesity, peripheral artery disease
ACE inhibitor use, angiotensin receptor blocker use, antidepressant use, antipsychotic
CHADS2 score, while the intracranial hemorrhage model was additionally adjusted for
\ǂ RDs for ischemic stroke calculated as the rate when off versus on therapy, while the Rbenefits were more modest than those observed with
warfarin. Finally, our results indicate that the net clinical
benefit of warfarin becomes apparent only after 3 months
of continuous use, highlighting the importance of im-
proving treatment persistence in patients using this
therapy.
To our knowledge, this is one of the largest population-
based studies to have evaluated the net clinical benefit ofanticoagulation intensity, and aspirin
Net clinical benefit
(strokes prevented per 100 persons/year) (95 % CI)
orrhage ǂ Weight = 1 Weight = 1.5 Weight = 2
0.63 (0.49, 0.77) 0.59 (0.45, 0.73) 0.56 (0.41, 0.70)
0.10 (−0.36, 0.56) 0.08 (−0.38, 0.54) 0.06 (−0.40, 0.52)
0.59 (0.33, 0.85) 0.57 (0.31, 0.83) 0.56 (0.30, 0.81)
−0.20 (−0.84, 0.44) −0.49 (−1.13, 0.15) −0.77 (−1.41, -0.13)
0.69 (0.54, 0.83) 0.65 (0.51, 0.80) 0.62 (0.47, 0.76)
3) −0.08 (−0.23, 0.07) −0.07 (−0.22, 0.08) −0.06 (−0.21, 0.09)
lized ratio.
, myocardial infarction, previous cancer, prior bleeds, thromboembolic disorders,
use, NSAID use, and statin use. The stroke model was additionally adjusted for
the components of that score.
Ds for intracranial hemorrhage calculated as the rate when on versus off therapy.
Figure 2 Net clinical benefit of warfarin, stratified according to CHADS2 score at baseline (based on an ICH weight of 1.5).
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that only 50% of the cohort was ever exposed to warfarin
during follow-up, demonstrating underutilization which is
consistent with other studies [4–6,22,23]. We also found
that patients with a history of stroke and those without aFigure 3 Net clinical benefit of aspirin, stratified according to CHADShistory of bleeds were the ones most likely to benefit from
warfarin therapy, thus identifying populations for whom
this therapy may or may not be appropriate. Finally, the
net clinical benefit of warfarin was maintained with longer
periods of continuous use. This novel finding emphasizes2 score at baseline (based on an ICH weight of 1.5).
Figure 4 Net clinical benefit of warfarin according to duration of continuous use (based on an ICH weight of 1.5).
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of patients with AF discontinue warfarin within the first
year of treatment [24,25].
As observed by others [9], we did not find any net
clinical benefit with aspirin overall. However, we did ob-
serve a net clinical benefit in patients with low CHADS2
scores (0 and 1), populations for whom aspirin is typically
indicated. These net clinical benefits were however, lower
than those observed with warfarin. Finally, while aspirin
had a net clinical benefit in patients with a history of
stroke, no benefit was observed in those with no history of
bleeds. Overall, our aspirin results need to be interpreted
with caution. Unlike warfarin, aspirin is available over-the-
counter, possibly leading to exposure misclassifications.
While chronic aspirin users typically receive prescriptions
for this drug, which is dispensed almost free of charge in
in the UK population, it is possible that some patients
were misclassified as unexposed, leading to an underesti-
mation of an already weak treatment effect.
This population-based study has a number of
strengths and some potential limitations. This was a
large population-based cohort of patients with AF, fol-
lowed for up to 16 years, enabling the identification of a
large number of cases. In addition, because medical and
drug information in the GPRD is prospectively col-
lected, the possibility of recall bias was eliminated.
However, drug information in the GPRD represents pre-
scriptions written by general practitioners. As such, it is
unknown whether prescriptions were actually filled atthe pharmacy and whether patients fully adhered with
the treatment regimen. Such non-differential misclassi-
fication of exposure would have biased the results to-
wards the null. Another limitation is that stroke events
may be underreported in the GPRD, which would lead
to an underestimation of the treatment effects. Further-
more, ischemic strokes were defined on the basis of a
specific diagnostic code for this event or a diagnostic
code of ‘stroke’ with no mention of the subtype. Since
stroke subtypes are not always specified in the GPRD
files, it is possible that some hemorrhagic strokes were
misclassified as being ischemic. However, this potential
bias is likely to have been minimal as the vast majority
of strokes are ischemic (>80%), and our overall rate was
very similar to the one reported in the previous study
(2.0% per year versus 2.1% per year, respectively) [8].
Finally, as with any observational study, confounding by
indication is a concern, whereby the risk profile of
patients prescribed warfarin or aspirin is likely to be dif-
ferent from the one of those not prescribed any antith-
rombotic therapy. Although we adjusted for a number
of potential confounding factors including BMI, exces-
sive alcohol use, and smoking which are often absent in
administrative databases, residual confounding may still
be present.
We assessed the net clinical benefit of warfarin and
aspirin on the basis of comparing their benefits in ische-
mic stroke prevention to their risks in increasing the
incidence of ICH. However, it would have been of
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prevention of MI in warfarin users [26]) to other risks
associated with these therapies, such as major bleeding
events (other than ICH). Unfortunately, the GPRD does
not collect detailed information to objectively classify
the severity of bleeding events (such as those events
requiring hospitalization, and those associated with
decreases in hemoglobin, or those requiring red blood
cell transfusions). Additional studies are needed to con-
sider the net clinical benefit of warfarin and aspirin in
the context of a broader range of outcomes.
In summary, our study provides the net clinical bene-
fit of warfarin and aspirin in patients with AF in the
natural setting of clinical practice. Our results indicate
that patients taking warfarin outside of the recom-
mended therapeutic range are unlikely to benefit from
this therapy, while aspirin confers a weak net clinical
benefit in selected populations. Finally, our findings
emphasize the need to identify high risk populations
that would benefit the most from warfarin therapy, and
ensure that such patients are maintained within thera-
peutic range, while identifying strategies to improve
treatment persistence.Additional file
Additional file 1: Algorithm to estimate warfarin exposure and
therapeutic range.
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